p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer?

被引:69
作者
Poller, DN
Baxter, KJ
Shepherd, NA
机构
[1] GLOUCESTERSHIRE ROYAL HOSP, DEPT HISTOPATHOL, GLOUCESTER GL1 3NN, ENGLAND
[2] GLOUCESTERSHIRE ROYAL HOSP, GLOUCESTER GASTROENTEROL GRP, GLOUCESTER GL1 3NN, ENGLAND
关键词
colorectal cancer; p53; Rb1; prognosis; cell cycle-associated protein;
D O I
10.1038/bjc.1997.14
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression of the p53 and Rb1 proteins was examined in an unselected consecutive series of 250 primary operable colorectal carcinomas with a mean follow-up of 4.3 years (range 43-77 months). The overall cancer-specific mortality was 34.8%, with 87 cancer deaths and 35 deaths as the result of other causes. Expression of p53 protein was identified in 152 of 250 (60.8%) cases, with expression of Rbl protein in 207 of 250 (82.8%) cases. There was no association of p53 or Rb protein expression with patient age, sex, tumour site, tumour size, tumour type, tumour grade, peritumoral fibrosis, tumour lymphocytic infiltrate, nature of the tumour margin, extramural vascular invasion, number of lymph nodes or high apical lymph node involved or local peritoneal infiltration by tumour, Dukes' stage or Jass group. There was no difference in overall survival or recurrence-free survival for those cases that showed p53 expression or Rb1 protein expression compared with those cases showing absence of p53 or Rbl protein expression, although patients with tumours showing aberrant (reduced) Rb1 protein expression demonstrated shorter recurrence-free survival and overall survival. The effect of 'aberrant' Rb1 protein expression and shorter recurrence-free and overall survival did not, however, achieve independent statistical significance. The results from this study would suggest that expression of p53 and Rbl proteins does not appear be useful in determining the prognosis of operable colorectal cancer.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 38 条
  • [11] P53 AND BEHAVIOR OF COLORECTAL-CANCER
    GOH, HS
    CHAN, CS
    KHINE, K
    SMITH, DR
    [J]. LANCET, 1994, 344 (8917) : 233 - 234
  • [12] ASSOCIATION OF P53 MUTATIONS WITH SHORT SURVIVAL IN COLORECTAL-CANCER
    HAMELIN, R
    LAURENTPUIG, P
    OLSCHWANG, S
    JEGO, N
    ASSELAIN, B
    REMVIKOS, Y
    GIRODET, J
    SALMON, RJ
    THOMAS, G
    [J]. GASTROENTEROLOGY, 1994, 106 (01) : 42 - 48
  • [13] INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER
    IGGO, R
    GATTER, K
    BARTEK, J
    LANE, D
    HARRIS, AL
    [J]. LANCET, 1990, 335 (8691) : 675 - 679
  • [14] ONCOGENIC FORMS OF P53 INHIBIT P53-REGULATED GENE-EXPRESSION
    KERN, SE
    PIETENPOL, JA
    THIAGALINGAM, S
    SEYMOUR, A
    KINZLER, KW
    VOGELSTEIN, B
    [J]. SCIENCE, 1992, 256 (5058) : 827 - 830
  • [15] MUTATIONS IN THE P53 GENE ARE NOT LIMITED TO CLASSIC HOT-SPOTS AND ARE NOT PREDICTIVE OF P53 PROTEIN EXPRESSION IN HIGH-GRADE NON-HODGKINS-LYMPHOMA
    KOCIALKOWSKI, S
    PEZZELLA, F
    MORRISON, H
    JONES, M
    LAHA, S
    HARRIS, AL
    MASON, DY
    GATTER, KC
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (01) : 55 - 60
  • [16] MOLECULAR-BIOLOGY OF BREAST-CANCER
    LEMOINE, NR
    [J]. ANNALS OF ONCOLOGY, 1994, 5 : S31 - S37
  • [17] MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
  • [18] ANTIGEN RETRIEVAL BY MICROWAVE IRRADIATION LOWERS IMMUNOHISTOLOGICAL DETECTION THRESHOLDS
    MCKEE, PH
    HOBBS, C
    HALL, PA
    [J]. HISTOPATHOLOGY, 1993, 23 (04) : 377 - 379
  • [19] P53 EXPRESSION, MUTATION, AND ALLELIC DELETION IN OVARIAN-CANCER
    MCMANUS, DT
    YAP, EPH
    MAXWELL, P
    RUSSELL, SEH
    TONER, PG
    MCGEE, JO
    [J]. JOURNAL OF PATHOLOGY, 1994, 174 (03) : 159 - 168
  • [20] CONDITIONAL INHIBITION OF TRANSFORMATION AND OF CELL-PROLIFERATION BY A TEMPERATURE-SENSITIVE MUTANT OF P53
    MICHALOVITZ, D
    HALEVY, O
    OREN, M
    [J]. CELL, 1990, 62 (04) : 671 - 680